JP2015508887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508887A5 JP2015508887A5 JP2014555851A JP2014555851A JP2015508887A5 JP 2015508887 A5 JP2015508887 A5 JP 2015508887A5 JP 2014555851 A JP2014555851 A JP 2014555851A JP 2014555851 A JP2014555851 A JP 2014555851A JP 2015508887 A5 JP2015508887 A5 JP 2015508887A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- patient
- inflammasome
- level
- cns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 59
- 108010034143 Inflammasomes Proteins 0.000 claims description 46
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 230000006378 damage Effects 0.000 claims description 28
- 210000003169 central nervous system Anatomy 0.000 claims description 26
- 239000012472 biological sample Substances 0.000 claims description 18
- 108090000426 Caspase-1 Proteins 0.000 claims description 15
- 102100035904 Caspase-1 Human genes 0.000 claims description 15
- 230000000324 neuroprotective effect Effects 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 12
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 claims description 10
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 claims description 10
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 6
- -1 ASC Proteins 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000003119 immunoblot Methods 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 229930182834 17alpha-Estradiol Natural products 0.000 claims description 3
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 claims description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 229940089161 ginsenoside Drugs 0.000 claims description 3
- 229930182494 ginsenoside Natural products 0.000 claims description 3
- 230000002631 hypothermal effect Effects 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 3
- 229960004023 minocycline Drugs 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- 206010010071 Coma Diseases 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108010000916 Fimbriae Proteins Proteins 0.000 claims description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 239000013068 control sample Substances 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 claims description 2
- 239000002082 metal nanoparticle Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 101100075486 Caenorhabditis elegans lrp-1 gene Proteins 0.000 claims 1
- 102000021350 Caspase recruitment domains Human genes 0.000 claims 1
- 108091011189 Caspase recruitment domains Proteins 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261595254P | 2012-02-06 | 2012-02-06 | |
| US61/595,254 | 2012-02-06 | ||
| PCT/US2013/024941 WO2013119673A1 (en) | 2012-02-06 | 2013-02-06 | Innate immune proteins as biomarkers for cns injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508887A JP2015508887A (ja) | 2015-03-23 |
| JP2015508887A5 true JP2015508887A5 (enExample) | 2016-02-25 |
| JP6170071B2 JP6170071B2 (ja) | 2017-07-26 |
Family
ID=48947960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555851A Active JP6170071B2 (ja) | 2012-02-06 | 2013-02-06 | Ｃｎｓ損傷についてのバイオマーカーとしての自然免疫タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20150185232A1 (enExample) |
| EP (1) | EP2812697B1 (enExample) |
| JP (1) | JP6170071B2 (enExample) |
| CA (1) | CA2863417C (enExample) |
| ES (1) | ES2630905T3 (enExample) |
| WO (1) | WO2013119673A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012142301A2 (en) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury |
| EP3129788A4 (en) * | 2014-04-08 | 2018-04-04 | University of Florida Research Foundation, Incorporated | Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system |
| WO2018126009A1 (en) | 2016-12-29 | 2018-07-05 | University Of Miami | Method for modulating inflammasome activity and inflammation in the lung |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| EP3685169A4 (en) * | 2017-09-20 | 2021-09-08 | University of Miami | PROCESS FOR DETECTION OF INFLAMMASOME PROTEINS AS BIOMARKERS OF NEUROLOGICAL DISORDERS |
| WO2019199869A1 (en) * | 2018-04-10 | 2019-10-17 | Quanterix Corporation | Quantification of biomarkers present in physiological samples |
| GB201815045D0 (en) | 2018-09-14 | 2018-10-31 | Univ Ulster | Bispecific antibody targeting IL-1R1 and NLPR3 |
| CN109406795A (zh) * | 2018-11-20 | 2019-03-01 | 昆明医科大学 | 一种轻型脑外伤的血清分子诊断标记物及应用 |
| WO2020157206A1 (en) * | 2019-01-31 | 2020-08-06 | University Of Geneva | Prospective markers in traumatic brain injury (tbi) |
| WO2021071934A1 (en) * | 2019-10-07 | 2021-04-15 | United States Government As Represented By The Department Of Veterans Affairs | Polymeric methylprednisolone conjugates and uses thereof |
| EP4142705A4 (en) * | 2020-04-27 | 2024-07-03 | University of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022156A2 (en) * | 2002-09-04 | 2004-03-18 | Washington University | Methods for treating central nervous system damage |
| US8685400B2 (en) * | 2007-07-30 | 2014-04-01 | University Of Miami | Modulating inflammasome activity and inflammation in the central nervous system |
| JP2011511301A (ja) * | 2008-02-04 | 2011-04-07 | バンヤン・バイオマーカーズ・インコーポレイテッド | 脳損傷を診断または治療するための方法 |
| WO2010008594A1 (en) * | 2008-07-18 | 2010-01-21 | Oxygen Biotherapeutics, Inc. | Method of treating traumatic brain injury |
| US20120177632A1 (en) * | 2011-01-10 | 2012-07-12 | Shinohara Mari L | Methods of optimizing disease treatment |
-
2013
- 2013-02-06 CA CA2863417A patent/CA2863417C/en active Active
- 2013-02-06 JP JP2014555851A patent/JP6170071B2/ja active Active
- 2013-02-06 EP EP13746979.7A patent/EP2812697B1/en active Active
- 2013-02-06 ES ES13746979.7T patent/ES2630905T3/es active Active
- 2013-02-06 WO PCT/US2013/024941 patent/WO2013119673A1/en not_active Ceased
- 2013-02-06 US US14/376,383 patent/US20150185232A1/en not_active Abandoned
-
2016
- 2016-07-20 US US15/214,868 patent/US20170003303A1/en not_active Abandoned
-
2020
- 2020-08-06 US US16/986,904 patent/US20200363432A1/en not_active Abandoned
-
2023
- 2023-07-05 US US18/347,108 patent/US20230349929A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508887A5 (enExample) | ||
| Green et al. | Non-genetic and genetic risk factors for adult cerebral venous thrombosis | |
| Bredrup et al. | Ciliopathies with skeletal anomalies and renal insufficiency due to mutations in the IFT-A gene WDR19 | |
| Daborg et al. | Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer’s disease | |
| Aly et al. | Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome | |
| Wilking et al. | Central nervous system manifestations in pediatric patients with influenza A H1N1 infection during the 2009 pandemic | |
| JP2021505844A5 (enExample) | ||
| Eijsvogel et al. | Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial | |
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| Tüzün et al. | Enhanced complement consumption in neuromyelitis optica and Behcet's disease patients | |
| KR20170062478A (ko) | 우울증 치료약의 선택지를 예측하는 방법 | |
| CN110573174A (zh) | 用于治疗脑损伤的方法和组合物 | |
| Kataria et al. | Sepsis biomarkers | |
| JP6608818B2 (ja) | 気分障害を診断、治療又は予防する方法 | |
| Arslan et al. | Importance of endothelial dysfunction biomarkers in patients with Crimean‐Congo hemorrhagic fever | |
| WO2019117270A1 (ja) | 頭頸部がんの検出を補助する方法 | |
| JP2018504909A5 (enExample) | ||
| Wei et al. | The first human infection with severe fever with thrombocytopenia syndrome virus in Shaanxi Province, China | |
| Vittorakis et al. | Circulating conventional and plasmacytoid dendritic cell subsets display distinct kinetics during in vivo repeated allergen skin challenges in atopic subjects | |
| Cummins et al. | Aging disrupts blood–brain and blood-spinal cord barrier homeostasis, but does not increase paracellular permeability | |
| Zhang et al. | MiR-18a-5p acts as a novel serum biomarker for venous malformation and promotes angiogenesis by regulating the thrombospondin-1/P53 signaling axis | |
| EP3918336A1 (en) | Prospective markers in traumatic brain injury (tbi) | |
| Gambichler et al. | Occurrence of circulating anti-bullous pemphigoid antibodies in patients with lichen sclerosus. | |
| WO2014080054A1 (es) | Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas |